Crunching the numbers for CE... Refresh in a moment for the full analysis.

Celanese Corp (CE)

Healthcare weak

$63.13

Updated: 2026-04-13

TradeApes Score

reduce

Financial Strength

50 Mixed

Operating Trend

10 Stressed

Valuation

50 Mixed

Capital Allocation

55 Mixed

Risk

80 Strong

Key Findings

+ Net cash position — more cash on hand than total debt

− Sharp revenue decline — sales down more than 15% year over year

See the full analysis

Quarterly financials, DCF valuation model, Watchlist, and Stock Screener.

Scores and valuations are model outputs, not investment advice. TradeApes does not provide financial, tax, or investment advice.